GIMV (EBR:GIMB) Gimv co-leads CHF 71M (USD 74M) Series B financing in ImmunOs Therapeutics to develop novel therapies in oncology and autoimmune disease.
Directive transparence : information réglementée INVESTMENT
07/06/2022 07:30
29/02/2024 07:45
27/02/2024 07:45
16/01/2024 07:30
19/12/2023 07:30
08/12/2023 12:00
30/11/2023 21:24
23/11/2023 06:58
20/09/2023 07:30
18/09/2023 07:29
11/09/2023 07:30